August 29, 2018


Media & events


Lyndra, Inc. and Allergan Sign a Partnership to Develop Ultra-Long-Acting Oral Products

September 7, 2017
Companies will collaborate to create products dosed once-weekly for the treatment of Alzheimer’s disease. Lyndra, Inc. (Lyndra) announced today a...
Read More

Lyndra Secures Funding from the National Institute of Allergy and Infectious Diseases for the Development of Ultra-Long Acting Oral HIV Therapies

May 2, 2017
Following their recent closing of a $23 Million Series A financing round, Lyndra, Inc. announced today that it has been...
Read More

Lyndra, Inc. Raises $23 Million in Series A Financing to Advance Ultra-Long Acting Oral Therapeutic Delivery

April 13, 2017
Lyndra, Inc. announced today the closing of a $23 Million Series A financing, led by Polaris Partners, with participation from...
Read More


Press Coverage